Literature DB >> 393383

Treatment of advanced gastric carcinoma with 5-fluorouracil: a randomized comparison of two routes of delivery.

R T Chlebowski, W S Paroly, R P Pugh, J M Weiner, J R Bateman.   

Abstract

Fifty-seven patients with advanced gastric carcinoma were randomized to receive 15 mg/kg/week of 5-fluorouracil by either the iv or oral route. Toxic effects of treatment included nausea and vomiting (40% with the oral route versus 35% with the iv route) and myelosuppression, with a wbc count of less than 4000/mm3 (28% with the oral route versus 32% with the iv route). The frequency of partial response was 12% (three of 25 patients) for the oral route and 16% (five of 32 patients) for the iv route. Only two of 36 patients with liver metastases responded. No advantage was seen for the oral versus the iv route of 5-fluorouracil in the treatment of advanced gastric carcinoma.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 393383

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  3 in total

1.  Systemic therapy for advanced gastric cancer: a clinical practice guideline.

Authors:  M Mackenzie; K Spithoff; D Jonker
Journal:  Curr Oncol       Date:  2011-08       Impact factor: 3.677

2.  5-fluorouracil vs. epirubicin vs. 5-fluorouracil plus epirubicin in advanced gastric carcinoma.

Authors:  P J Loehrer; D Harry; R T Chlebowski
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

Review 3.  Chemotherapy for advanced gastric cancer.

Authors:  Anna Dorothea Wagner; Nicholas Lx Syn; Markus Moehler; Wilfried Grothe; Wei Peng Yong; Bee-Choo Tai; Jingshan Ho; Susanne Unverzagt
Journal:  Cochrane Database Syst Rev       Date:  2017-08-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.